New drug targets rare genetic glitch in advanced cancers
NCT ID NCT06385496
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests the drug MLN0128 (TAK-228) in 35 patients with advanced cancers (solid tumors, lymphoma, or multiple myeloma) that have a specific genetic change called an mTOR mutation. The drug works by blocking enzymes that cancer cells need to grow. Researchers will measure how many patients' tumors shrink or stop growing, and track survival over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MLN0128 (TAK-228)
- What this could lead to
- If it works, this could point toward a targeted treatment option for people with cancers that have specific mTOR mutations.
- What could go wrong
- This is a small, early-phase trial (35 participants) with no control group, so results may not apply broadly. The drug may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two drug punch beat back Hard-to-Treat myeloma?
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Experimental antibody drug shows promise for Hard-to-Treat lymphoma
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Engineered immune cells take aim at Hard-to-Treat cancers
- Double-barreled CAR t therapy takes aim at hard-to-treat myeloma